MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.

With the Own It effort, Medtronic is providing a way for those living with diabetes to celebrate ordinary moments made possible with the right technology so they can own every choice.

MiniMed has filed IPO registration with SEC as Medtronic moves forward with the spin off of its diabetes division.

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S ...

Medtronic plc MDT announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor (CGM) used with the MiniMed 670G insulin pump. Notably, the Guardian ...

GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...

Medtronic PLC has received approval to sell a device for diabetes patients that displays insulin levels on Internet-enabled devices and sends text messages to loved ones if something goes wrong. At an ...

Medtronic plcMDT announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor (CGM) used with the MiniMed 670G insulin pump. Notably, the Guardian ...